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• GAS showed aggressive behavior with ominous histopathological predictors as well as decreased survival.
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Available online 29 January 2019Objective. Gastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine
cervix. As shown in the original Japanese group description, in recent studies, GAS represents a more aggressive
disease than the usual-type endocervical adenocarcinoma (UEA). Detailed clinicopathological features of this
variant remain to be elucidated in a larger series of patients.
Methods. Patients were enrolled by the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group
after receiving the approval of each Institutional Review Board. The study population comprised of womenwith
stage I to II endocervical adenocarcinomas who underwent surgery between 2000 and 2009. Representative
slides were evaluated by central pathological review (CPR), categorized into either GAS or UEA, and correlated
with clinicopathological features and outcome.
Results.Among the 393 enrolled patientswith endocervical adenocarcinoma, 328 patientsmet the criteria for
CPR and the study eligibility criteria and were included in further analysis. A total of 95 of the 328 tumors were
classiﬁed as GAS. Compared with UEA, GAS was more signiﬁcantly associated with bulky mass, deep stromal in-
vasion, lymphovascular space invasion, parametrial invasion, ovarian metastasis, positive ascitic ﬂuid cytology,Keywords:
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14 S. Nishio et al. / Gynecologic Oncology 153 (2019) 13–19pelvic lymph node metastasis, and pathological (p) T stage but was not related to the degree of histological dif-
ferentiation. Disease-free survival (P b 0.0001) and overall survival (P b 0.0001)were poorer in patientswith GAS
than in those with UEA.
Conclusions.GAS showed aggressive behaviorwith ominous histopathological predictors aswell as decreased
survival. GAS is therefore considered a distinct entity that should be distinguished from UEA.
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Uterine cervical cancer is the third most common cancer in women,
with 528,000 new cases diagnosed each year, and it accounts for
266,000 annual deathsworldwide [1]. During the past decade, the prev-
alence of adenocarcinoma of the uterine cervix increased from approx-
imately 5% to 20% of cervical cancers [2]. Recently, a number of authors
have reported that the 5-year overall survival rate is 10% to 20% lower in
nonsquamous cell carcinoma (non-SCC) than in SCC [3,4]. Additionally,
recent studies have provided evidence that adenocarcinoma clearly dif-
fers from SCC with respect to its molecular pathogenesis [5,6]. There-
fore, it was suggested that the histological type should be considered
when deciding on treatments for patients with cervical cancer [2,7].
Otherwise, adenocarcinomas of the cervix are related to persistent
high-risk human papillomavirus (HPV) infection [8–11].
However, there is an emerging spectrum of non–HPV-related cervi-
cal adenocarcinomas. For example, in a recent large European study
with centralized pathology review and sensitiveHPVdetectionmethods,
high-risk HPV was detected in over 90% of usual-type adenocarcinomas
(UEA), whereas the detection rates were much lower in other morpho-
logic variants; for example, 28% was reported in clear cell carcinomas
[12]. It has become clear recently that the most common variant of
non-HPV-related cervical adenocarcinoma belongs to a spectrum of
adenocarcinomas.
Gastric-typemucinous carcinoma (GAS) of the uterine cervix is a rel-
atively newly recognized variant of endocervical adenocarcinoma. GAS
was initially described by Japanese groups [14–16] and was included
as a subtype of endocervical mucinous adenocarcinoma in the World
Health Organization (WHO) classiﬁcation updated in 2014 [17]. It is
deﬁned as a mucinous carcinoma with gastric-type differentiation and
includes minimal deviation adenocarcinoma (MDA), also known as ad-
enomamalignum because of its morphologic spectrum [17]. In contrast
to UEA, GAS is frequently located in the upper endocervix and shows a
bulky cervixwithout awell-demarcatedmass because of its highly inﬁl-
trating pattern of growth [18]. Whereas most UEAs are HPV-related,
GAS is reported to be unrelated to HPV and is importantly associated
with an aggressive clinical behavior, resulting in poorer outcomes
than those of UEA [8,9,16,19,20]. Although GAS is considered rare in
Western countries [12], it is rather common in Japan, accounting for
up to 20% to 25% of all endocervical adenocarcinomas [16,19]. Therefore,
the discrepancies in the data used to determine the outcomes in pa-
tients with endocervical adenocarcinoma might reﬂect differences in
the incidences of GAS reported in each study.
A Japanese group reported that GAS represents more aggressive dis-
ease than does UEA [21]. However, this remains to be conﬁrmed in a
larger series of patients. Here we examine whether GAS represents a
more aggressive disease than does UEA in a larger series.2. Methods
Patients were enrolled by the Gynecologic Cancer Study Group of
the Japan Clinical Oncology Group (JCOG-GCSG) after receiving ap-
proval from each Institutional Review Board (study ID designated
as UMIN000007987 by the UMIN Clinical Trials Registry). The study
population comprised of women with stage I to II disease whounderwent surgery without receiving neoadjuvant chemotherapy
between 2000 and 2009.
All patients underwent radical hysterectomywith pelvic lymphade-
nectomy or para-aortic lymph-node biopsy, or both. The pelvic lymph
node dissection included bilateral removal of the external iliac
(suprainguinal), internal iliac, obturator, and common iliac lymph
nodes. Para-aortic lymph-node biopsy was performed from the aortic
bifurcation to the level of the renal vessels. Patients with deep stromal
invasion, lymphovascular invasion, parametrial invasion, and lymph
node metastases were administered adjuvant therapy. After surgery,
131 patients (197 patients did not) received post-operative adjuvant
therapy. External beam radiotherapy was performed with 50.4 Gy to
the entire pelvis. Intracavitary brachytherapy was performed if the sur-
gical margin of the vaginal cuff was involved histologically or if the free
margin measured b1 cm.
Representative glass slides of all cases were evaluated by central
pathological review (CPR) on the basis of the currentWHOclassiﬁcation
updated in 2014 to determine the differences in the clinicopathological
features between GAS and UEA. Additionally, the outcomes in patients
with each type of diseasewere statistically compared. In a CPR of hyster-
ectomy specimens, two of the authors (Y.M. and T.K.), who are board-
certiﬁed pathologists specializing in gynecological pathology and oncol-
ogy, reviewed representative glass slides, without providing themwith
any clinical information or the original histopathological diagnosis.
Morphologically, GAS was deﬁned as mucinous carcinoma showing
(i) clear or pale eosinophilic cytoplasm, (ii) voluminous cytoplasm,
and (iii) distinct cell borders, whereas UEA was deﬁned as mucin-
deﬁcient or mucin-poor carcinoma that does not meet the criteria for
any other subtype of endocervical adenocarcinoma. All relevant patho-
logical and clinical data were collected and analyzed.
2.1. Statistical analysis
The statistical signiﬁcance of differences in the proportions of cases
within each histologic group having various pathologic or clinical fea-
tures was assessed using Fisher's exact test [22]. The survival time of
each patient was calculated from the date of diagnosis to date of
death, with right-censoring at the date of the last follow-up for patients
who were still alive. The cumulative survival probabilities for each
group of patients were estimated by life-table methods, commonly re-
ferred to as the Kaplan-Meier method [23]. The log-rank test was used
to compare two survival curves [24,25].
P-values of b0.05 indicate statistical signiﬁcance, unless otherwise
stated. For survival analysis, data on overall survival (OS)were censored
from the date of surgery to the date of the last follow-up; events were
deﬁned as death from any cause. Data on progression-free survival
(PFS) were censored from the date of surgery to the date of the last
follow-up if disease progression had not occurred; events were deﬁned
as death fromany cause, disease relapse, and disease progression. All re-
ported P-values are two-sided. Statistical analysis was performed with
SAS, version 9.1 (SAS Institute, Inc., Cary, NC) and revised version 2.7.0.
2.2. HPV studies
Parafﬁn-embedded tissue samples were cut at a thickness of 10 μm
and placed on coated glass slides. HPV testing was performed in 31
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Diagnostics, Pleasanton, CA) was performed. The Roche linear array
HPV genotyping test involves polymerase chain reaction ampliﬁcation
of target DNA followed by hybridization for the detection of 37 HPV
types, including 18 high-risk types (16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 73, 82) and 19 low-risk types (6, 11, 40, 42,
54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, IS39, CP108).3. Results
A total of 393 patients with endocervical adenocarcinoma were en-
rolled in our project. Sixty-ﬁve patients were ineligible for this study ac-
cording to CPR or because of insufﬁcient or wrong clinical information
(25 patients had stage III or IV disease, and 40patients had the following
histologic types: lobular endocervical glandular hyperplasia [LEGH] in 5
patients, adenocarcinoma in situ (AIS) in 18 patients, endometrioid car-
cinoma in 10 patients, undifferentiated carcinoma in 5 patients, and se-
rous carcinoma in 5 patients). Thus, 328 patients with endocervical
adenocarcinomas were included in this study, and of the tumors, 95
(28.9%) were re-classiﬁed as GAS. The patients' characteristics are
shown in Table 1. The median age of the patients was 45 years (range:
21–79). The median tumor marker level was 15 U/mL (range:
0.6–900.3) for CA125, 13 U/mL (range: 0.1–5850.2) for CA19–9, and
1.6 ng/mL (range: 0.2–351.3) for CEA. The median tumor diameter
was 20 mm (range: 2–64.1). The pathological T stage and the degree
of differentiation are shown in Table 1. Among the 131 patients who re-
ceived postoperative adjuvant therapy (197 patients [60.1%] did not),
radiotherapy, concurrent chemoradiotherapy, chemotherapy, and che-
motherapy plus radiotherapy, were administered to 41 (12.5%), 22
(6.7%), 66 (20.1%), and 2 (0.6%) patients, respectively.
ComparedwithUEA, GASwas signiﬁcantly associatedwith tumor di-
ameter of b40mm(bulkymass), deep stromal invasion, lymphovascular
invasion, parametrial invasion, ovarian metastasis, positive asciticTable 1
Patient characteristics (n= 328).
Factor N (%)
Age (range) 45 (21–79)
FIGO Stage (1988)
IA 19 (5.8)
IB1 224 (68.3)
IB2 44 (13.4)
IIA 9 (2.7)
IIB 32 (7.8)
Tumor marker median (range)
CA125 (U/mL) 15 (0.6–900.3)
CA19-9 (U/mL) 13 (0.1–5850.2)
CEA (ng/mL) 1.6 (0.2–351.3)
Tumor diameter (mm) median (range) 20 (2–64.1)
pT Stage
Ia 22 (6.7)
Ib1 198 (60.4)
Ib2 43 (13.1)
IIa 22 (6.7)
IIb 43 (13.1)
Differentiation
Well 233 (71)
Moderately 48 (14.6)
Poorly 17 (4.3)
Unclassiﬁed 40 (10.1)
Adjuvant therapy
None 197 (60.1)
Radiotherapy 41 (12.5)
Concurrent chemoradiotherapy 22 (6.7)
Chemotherapy 66 (20.1)
Chemotherapy + Radiotherapy 2 (0.6)
FIGO, International Federation of Gynecology and Obstetrics; CA 125, cancer antigen 125;
CA19-9, carbohydrate antigen 19-9; serum carcinoembryonic antigen (CEA).cytology, pelvic lymph node metastasis, and pT factor, but there was
no correlation with tumor differentiation (Table 2). The results of
Kaplan–Meier analysis are shown in Fig. 2. The median PFS was
61.1 months in patients with UEA and 42 months in patients with
GAS. PFS and OS were poorer in patients with GAS than in patients
with UEA (Fig. 1).
Table 3 shows the results from the univariate andmultivariate Cox re-
gression models, respectively. Variables signiﬁcantly associated in the
univariate analysis with PFS and OS included, tumor diameter (≥40 mm
vs. b40 mm; hazard ratio [HR] 3.408, 95% CI, 1.705–6.812; P = 0.0005
and 4.3, 95% CI, 1.942–9.522; P=0.0003, respectively), parametrial inva-
sion (present vs. absent; HR 3.012, 95% CI, 1.112–8.658; P= 0.0306 and
4.577, 95% CI, 1.338–15.66; P = 0.0154, respectively), differentiation
(poorly differentiated vs. moderately and well differentiated; HR 3.228,
95% CI, 1.771–5.884; P = 0.0001 and 2.978, 95% CI, 1.499–5.918; P =
0.0018, respectively), ovarian metastasis (present vs. absent; HR 19.014,
95% CI, 4.582–78.894; P b 0.0001 and 18.362, 95% CI, 3.684–91.526; P=
0.0004, respectively), and GAS (present vs. absent; HR 2.365, 95% CI,
1.287–4.347; P=0.0056 and 2.984, 95% CI, 1.485–5.996; P=0.0021, re-
spectively). In contrast, pT stage, stromal invasion, lymph node metasta-
sis, and ascites cytology positive had no effect on survival.
Variables signiﬁcantly associated in the multivariable analysis
with PFS and OS included tumor diameter (≥40 mm vs. b40 mm;
HR 3.406, 95% CI, 1.824–6.3612; P = 0.0001 and 4.378, 95% CI,
2.105–9.107; P b 0.0001, respectively), parametrial invasion (pres-
ent vs. absent; HR 3.461, 95% CI, 1.864–6.428; P b 0.0001 and 2.885,
95% CI, 1.416–5.879; P=0.0035, respectively), lymph nodemetasta-
sis (present vs. absent; HR 2.286, 95% CI, 1.262–4.14; P=0.0064 and
2.48, 95% CI, 1.269–4.847; P = 0.0079, respectively), differentiation
(poorly differentiated vs. moderately and well differentiated; HR
3.031, 95% CI, 1.665–5.515; P = 0.0003 and 3.057, 95% CI, 1.535–6.09;
P = 0.0015, respectively), ovarian metastasis (present vs. absent; HRTable 2
Comparison of clinicopathological factors between GAS and UEA.
Factor Histology P-value
GAS UEA
pT Stage P b 0.0001
Ia 4 18
Ib1 33 165
Ib2 22 21
IIa 12 10
IIb 24 19
Tumor diameter P b 0.0001
b40 mm 50 189
≥40 mm 45 44
Stromal invasion P b 0.0001
b2/3 38 183
≥2/3 57 50
Lymphovascular space invasion P b 0.0001
Present 63 71
Absent 32 162
Parametrial invasion P b 0.0001
Present 25 17
Absent 70 216
Lymph node metastasisa P b 0.0001
Present 33 33
Absent 57 192
Differentiationa P= 0.2716
Well 66 167
Moderate, Poorly 23 42
Ovary metastasis P= 0.0481
Present 5 3
Absent 90 230
Ascites cytologya P= 0.0136
Positive 10 8
Negative 77 197
GAS, gastric-type mucinous carcinoma; UEA, usual-type endocervical adenocarcinoma.
a Including missing data.
Fig. 1. Progression-free survival and overall survival: blue line, UEA group; red line, GAS group.
16 S. Nishio et al. / Gynecologic Oncology 153 (2019) 13–199.173, 95% CI, 3.349–25.123; P b 0.0001 and 12.178, 95% CI,
4.178–35.494; P b 0.0001, respectively), and GAS (present vs. absent;
HR 2.361, 95% CI, 1.333–4.182; P = 0.0032 and 3.034, 95% CI,
1.566–5.877; P= 0.001, respectively).
When stratiﬁed according to stage, patients with pT1a-pT1b1 ade-
nocarcinoma had poorer outcomes, but the difference between groups
with pT1b2 or more was not signiﬁcant (Fig. 2A, B).3.1. HPV results
Linear array HPV genotyping was negative in the 31 patients in
whom it was performed.3.2. Recurrence course
Overall, recurrence occurred in 72 of the 328patients: 38 (40%) of 95
patients with GAS and 34 (14.6%) of 233 patients with UEA. Recurrence
was clearly more common among patients with GAS (P = 0.0023). In
the GAS group, the sites of recurrence were local in 15 patients, distant
in 15, and local plus distant in 8. In theUEA group, the sites of recurrence
were local in 19 patients, distant in 11, and local plus distant in 4, with
no signiﬁcant difference between the groups (Table 4). Following recur-
rence, chemotherapy was administered to 19 patients with GAS, with a
response rate of 36.8% (7/19), and to 25 patients with UEA, with a re-
sponse rate of 32.0% (8/25). The difference in the response rates was
not signiﬁcant.
Table 3
The effect on survival by univariate(A) analysis and multivariate(B) analysis.
Factor P-value Hazard Ratio 95% CI
PFS OS PFS OS PFS OS
A
pT stage P= 0.5947 P= 0.3366 1.294 0.562 0.501–3.341 0.164–1.82
Tumor diameter P= 0.0005 P= 0.0003 3.408 4.3 1.705–6.812 1.942–9.522
Stromal invasion P= 0.2651 P= 0.6162 1.618 1.275 0.694–3.772 0.493–3.298
Lymph vascular space invasion P= 0.3039 P= 0.8944 0.09 1.055 0.34–1.4 0.476–2.343
Parametrial invasion P= 0.0306 P= 0.0154 3.102 4.577 1.112–8.658 1.338–15.66
Lymph node metastasis P= 0.0507 P= 0.033 1.932 2.24 0.998–3.739 1.067–4.699
Differentiation P= 0.0001 P= 0.0018 3.228 2.978 1.771–5.884 1.499–5.918
Ovary metastasis P b 0.0001 P= 0.0004 19.014 18.362 4.582–78.894 3.684–91.526
Ascites cytology P= 0.1633 P= 0.8607 0.458 0.897 0.153–1.373 0.266–3.025
GAS P= 0.0056 P= 0.0021 2.365 2.984 1.287–4.347 1.485–5.996
B
Tumor diameter P= 0.0001 P b 0.0001 3.406 4.378 1.824–6.361 2.105–9.107
Parametrial invasion P b 0.0001 P= 0.0035 3.461 2.885 1.864–6.428 1.416–5.879
Lymph node metastasis P= 0.0064 P= 0.0079 2.286 2.48 1.262–4.14 1.269–4.847
Differentiation P= 0.0003 P= 0.0015 3.031 3.057 1.665–5.515 1.535–6.09
Ovary metastasis P b 0.0001 P b 0.0001 9.173 12.178 3.349–25.123 4.178–35.494
GAS P= 0.0032 P= 0.001 2.361 3.034 1.333–4.182 1.566–5.877
CI, conﬁdence interval; PFS, progression-free survival; OS, overall survival; GAS, gastric-type mucinous carcinoma.
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sponse rate of 50.0% (6/12), and to 11 patients with UEA, with a re-
sponse rate of 81.8% (9/11, P b 0.0001). GAS was thus signiﬁcantly
more resistant to radiotherapy.
4. Discussion
Currently, endocervical adenocarcinoma is considered to be a
heterogeneous group of tumors showing signiﬁcant clinical, etio-
logic, and morphologic diversity, and the implication of high-risk
HPV has become a crucial issue [26,27]. In the 2014 WHO classiﬁca-
tion, mucinous adenocarcinoma was distinguished from UEA and in-
cluded gastric, intestinal, and signet ring-cell types, whereas MDA
was regarded as the highly differentiated form of GAS [17]. Our
work and that of other investigators support the conclusion that
GAS constitutes a unique tumor typewith distinct etiologic, morpho-
logic, and clinical features that set it apart from other mucinous car-
cinomas [8,9,11,16,19]. This present work conﬁrms the conclusion
offered by Kojima et al. [16] and builds on it. GAS is a clinically ag-
gressive neoplasm with a distinctive histologic appearance. To our
knowledge, our study of 328 patients with mucinous endocervical
adenocarcinoma, including 95 patients with a diagnosis of GAS, is
the largest study of its type in the world.
Karamurzin et al. [20] showed that GAS typically presents at a
more advanced stage than HPV-associated UEA, and survival anal-
ysis restricted to patients with International Federation of Gyne-
cology and Obstetrics (FIGO) stage I tumors indicated that GAS
remained more aggressive. In our study, the proportion of patients
with GAS markedly increased as the disease stage progressed
(Table 2). However, although GAS was associated with poorer
outcomes than those of UEA in patients with Ia-Ib1-stage disease,
there was no difference in outcomes in patients with Ib2-II-stage
disease (Fig. 2A, B). This ﬁnding suggests that GAS might be associ-
ated with poorer outcomes among patients with early-stage
cancer.
Our study clearly shows that recurrence was more common among
patients with GAS (P = 0.0023). In the GAS group, the sites of recur-
rence were local in 15 patients, distant in 15, and local plus distant in
8. In the UEA group, the sites of recurrencewere local in 19 patients, dis-
tant in 11, and local plus distant in 4, with no signiﬁcant difference be-
tween the groups. In a previous study, there was also no difference in
the sites of recurrence between GAS and UEA [20].The diagnosis of GAS is established primarily based on morphol-
ogy; among pathologists, reproducibility is conﬁrmed to be optimal
according to their familiarity with the histopathological criteria of
GAS [28]. However, immunohistochemistry may contribute to the
establishment of the diagnosis, particularly in cases of small biopsy
specimen. GAS typically shows the gastric phenotype, as demon-
strated by HIK1083, MUC6, or carbonic anhydrase type IX staining,
and is negative for p16. Additionally, it frequently shows a mutant
pattern of p53 staining [29]. Although we did not perform immuno-
histochemical analysis in our study, the concordance rate of the cen-
tral pathological evaluation by the expert panel was 98.9% (94/95),
suggesting that ancillary studies might not always be required for
the diagnosis of GAS. On the other hand, the results of HPV DNA
tests were negative in all 31 patients in whom such examinations
were performed, suggesting that HPV tests may be useful for the di-
agnosis of GAS.
The results of our multivariable analysis showed that along
with GAS, the following factors were also predictors of the
outcomes: tumor diameter ≥40 mm, parametrial invasion, lymph
node metastasis, poorly differentiated cancer, and ovarian
metastasis.
Since the ﬁrst description of GAS in 2007, some authors have
reported its poorer outcomes than those of UEA in retrospective
studies [16,26]. However, the cause of its aggressive behavior
remained unknown; possibilities such as difﬁculty in early detection,
chemoresistance, and radioresistance were considered. Kojima et al.
[21] showed signiﬁcant differences in chemosensitivity and survival
outcomes between UEA and GAS in patients for whom chemother-
apy regimens had been strategically selected and who were prospec-
tively followed up in a phase 2 study.
Among patients who had recurrence in our study, radiother-
apy was administered to 12 patients with GAS, with a response
rate of 50.0% (6/12), and to 11 patients with UEA, with a re-
sponse rate of 81.8% (9/11, P b 0.0001). GAS was thus signiﬁ-
cantly more resistant to radiotherapy. Such resistance to
chemotherapy and radiotherapy might contribute to the poorer
outcomes in GAS.
Recently, a large comprehensive genomic study of 228 patients
with cervical cancer reported that patients with endometrial-like
cervical cancers, which mainly comprised HPV-negative tumors,
had relatively high frequencies of KRAS, ARID1A, and PTEN muta-
tions [30]. Such molecular analyses may lead to a breakthrough,
Fig. 2. A: Survival curve of patients with pT1a-1b1 and pT1b1: PFS, progression-free survival; overall survival; blue line, UEA group; red line, GAS group. B: Survival curve of patients with
pT1b2 and pT2: blue line, UEA group; red line, GAS group; N.S., not signiﬁcant.
18 S. Nishio et al. / Gynecologic Oncology 153 (2019) 13–19revealing new potential therapeutic targets for lethal cervical cancer,
such as GAS.
To achieve better oncologic outcomes in patients with locally ad-
vanced, aggressive types of cervical cancer such as GAS, various mul-
tidisciplinary treatment strategies incorporating cisplatin-based
concurrent chemoradiotherapy and molecular targeted therapy
have been evaluated. However, the proﬁles of the genomic signa-
tures of unusual cervical cancers, represented by GAS as well as
clear cell carcinoma and serous carcinoma, are still limited, and
deﬁnitive treatment guidelines for such cancers remain to be
established.
In conclusion, GAS is signiﬁcantly associated with histopathological
predictors of poor outcomes as well as with poorer survival outcomesand is therefore considered a distinct entity that should bedistinguished
from UEA. Further research needs to elucidate molecular mechanism
and genomic study for GAS.
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Table 4
Sites of recurrencea (n= 72).
Site GAS UEA
Brain 1 0
Lung 10 9
Liver 2 3
Peritoneum 3 1
Bone 2 0
Abdominal lymph node 6 9
Pelvic lymph node 6 7
Pelvis 8 5
Vaginal cuff 10 9
Local site 15 11
Distant site 15 19
Local site + Distant site 8 4
GAS, gastric-type mucinous carcinoma; UEA, usual-type endocervical adenocarcinoma.
a Duplicated cases included.
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